Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids

Archimedes Development

Status and phase: Completed; Phase 3

Conditions: Cancer Pain

Treatments: Drug: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00459277

CPO43/06/FCNS

Details and patient eligibility

About

Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment. Fentanyl is a strong, short-acting pain killer often used to treat this 'breakthrough' pain. Nasalfent contains fentanyl in a patented drug delivery system called PecSys and is given via a simple nasal spray. This study will test the efficacy and safety of Nasalfent in the treatment of breakthrough cancer pain.

Full description

Current treatments for breakthrough cancer pain (BTCP) work too slowly to meet the fast onset of most BTCP episodes, they continue to act longer than the episode of pain lasts and so can have unwanted side effects due to this 'over treatment' of the pain episode. In addition most cancer patients have oral problems which make taking pain relief medication by mouth uncomfortable for the patient. Nasalfent is administered via the nose as a simple spray and can be taken by patients or given by their carers. The nasal route is a common way to administer medication for example in the treatment of migraine or allergy. At any time during the study the patient may take their regular treatment for BTCP should they so wish.

This study will compare the time of onset and degree of pain relief of Nasalfent to that of Placebo. The safety of the two treatments groups (Nasalfent, Placebo) will also be examined.

Enrollment: 73 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Able and willing to give consent
• Women of childbearing potential must have a) negative urine pregnancy test b) not be breast feeding c) agree to practice a reliable form of contraception
• Diagnosis of cancer
• Taking at least 60mg oral morphine or equivalent as 24 hour treatment for cancer-related pain
• Experiencing on average 1 - 4 episodes of breakthrough cancer pain per day usually controlled by rescue pain medication
• Able (or via caregiver)to evaluate and record pain relief, assess medication performance at set times after dosing, record adverse events, record each use of the study drug or rescue medication in a diary
• Able to be up and about for 50% of the day or greater

Exclusion criteria

• Intolerance to opioids or fentanyl
• rapidly increasing/uncontrolled pain
• pain that is not cancer related

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

73 participants in 2 patient groups, including a placebo group

Nasalfent, Fentanyl Citrate Nasal Spray

Experimental group

Treatment:

Drug: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)

Placebo Spray

Placebo Comparator group

Treatment:

Drug: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)